Table 1.
HPLC gradient parameters used to separate tamoxifen and its metabolites using a ZORBAX Eclipse XDB-C18 column (150 mm x 2.1 mm I.D., 3.5 µm) at 30°C.
Table 2.
HPLC and MS parameters used to discriminate tamoxifen and its metabolites.
Table 3.
CYP2D6, CYP3A4, CYP3A5, SULT1A1, SULT1A2 and SULT1E1 genotype frequencies.
Table 4.
CYP2D6, CYP3A4, CYP3A5, SULT1A1, SULT1A2 and SULT1E1 allele frequencies. International codes for SNPs between parentheses.
Table 5.
Concentrations of tamoxifen and its metabolites (means (±SD), medians (in cursive) and ranges (in parentheses)) detected in patients with the CYP2D6, CYP3A4 and CYP3A5 genotypes.
Table 6.
Concentrations of tamoxifen and its metabolites (means (±SD), medians (in cursive) and ranges (in parentheses)) detected in patients with the SULT1A1, SULT1A2 and SULT1E1 genotypes.
Figure 1.
Concentrations of tamoxifen and its metabolites (means ± standard deviations, ng/mL) by CYP2D6 and SULT1A2 genotype subgroups established according to wt allele doses.
Sample sizes: CYP2D6: wt/wt = 80; wt/v = 30; v/v = 11//SULT1A2: wt/wt = 38; wt/v = 49; v/v = 34.